White Paper

Benefits Of PCR-Based mRNA Manufacturing Processes

By Eike Joest, Ph.D., Principal Scientist, mRNA Innovation, and Julian Mochayedi, Ph.D., Strategic Marketing Manager, mRNA Solutions

Developing mRNA Vaccines GettyImages-1307593959

mRNA is one of the most prominent and promising modalities for vaccines and therapeutics. Although the development of COVID-19 vaccines occurred at unprecedented speed, ongoing innovations in manufacturing technologies are essential for the successful advancement of new mRNA applications. Typically, the production of these therapeutics and vaccines starts with generating a large quantity of plasmid DNA (pDNA) followed by linearization utilizing restriction enzymes. This is a time-consuming and resource-intensive process, as the need for sufficient quantity and quality of pDNA can create bottlenecks in the manufacturing workflow. Additionally, extensive use of genetically modified bacteria and antibiotics presents challenges in maintaining good manufacturing practices (GMP).

To overcome the challenges and bottlenecks associated with pDNA, a proprietary polymerase chain reaction (PCR) solution has been developed to combine the high quality benefits of synthetic templates with accuracy and scalability. Continue reading to learn more about this solution that applies the high accuracy of PCR to mRNA manufacturing.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online